2018 Press Releases

Webcast ImageWebcast
AVEO Oncology at the LEERINK Partners 7th Annual Global Healthcare Conference (Replay)
02/14/18 at 10:00 a.m. ET
AVEO Oncology at the LEERINK Partners 7th Annual Global Healthcare Conference
Wednesday, February 14, 2018 10:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
AVEO Oncology at the RBC Capital Markets Healthcare Conference (Replay)
02/21/18 at 10:00 a.m. ET
AVEO Oncology at the RBC Capital Markets Healthcare Conference
Wednesday, February 21, 2018 10:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
02/12/18AVEO Announces EUSA Pharma Granted Positive NICE Recommendation for FOTIVDA® (tivozanib) as First Line Treatment for Advanced Renal Cell Carcinoma
Recommendation Triggers $2M Milestone Payment from EUSA to AVEO CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 12, 2018-- AVEO Oncology (NASDAQ:AVEO) today announced that the United Kingdom’s National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending FOTIVDA® (tivozanib) for the first line treatment of adult patients with advanced renal cell carcinoma (aRCC). In the European Union, Norway and Ic... 
Printer Friendly Version
02/10/18AVEO Oncology and EUSA Pharma Announce Encouraging Preliminary Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma
Data Presented at the 2018 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) CAMBRIDGE, Mass. & HEMEL HEMPSTEAD, England--(BUSINESS WIRE)--Feb. 10, 2018-- AVEO Oncology (NASDAQ: AVEO) and EUSA Pharma today announced the presentation of preliminary results from the Phase 2 portion of the TiNivo study, a Phase 1b/2 multicenter trial of oral (PO) tivozanib (FOTIVDA®) in combination with intravenous (IV) nivolumab ... 
Printer Friendly Version
02/07/18AVEO Oncology to Present at Upcoming Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 7, 2018-- AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the following investor conferences: LEERINK Partners 7th Annual Global Healthcare Conference on Wednesday, February 14, 2018 at 10:00 a.m. Eastern Time. The conference is being held at the Lotte New York Palace Hotel. RBC Capital Markets He... 
Printer Friendly Version
02/01/18AVEO Announces Appointment of John H. Johnson to Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 1, 2018-- AVEO Oncology (NASDAQ: AVEO) today announced the appointment of John H. Johnson to the Company’s Board of Directors. Mr. Johnson brings to AVEO over three decades of experience in the biotechnology and pharmaceuticals industries, having held commercial and executive management roles at leading global corporations that have a focus on oncology, including Johnson & Johnson, Eli Lilly & Company, ImCl... 
Printer Friendly Version
01/19/18AVEO Oncology Announces Presentation of Data from Phase 1b/2 Study of Tivozanib in Patients with Advanced Hepatocellular Carcinoma
Poster Presentation Delivered at the 2018 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 19, 2018-- AVEO Oncology (NASDAQ:AVEO) today announced the presentation of data from a multicenter, Phase 1b/2 study of FOTIVDA® (tivozanib), a potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors, in patients with advanced, unre... 
Printer Friendly Version
01/04/18AVEO Oncology to Present at the 36th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2018-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 11, 2018 at 11:30 a.m. Pacific Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of t... 
Printer Friendly Version
01/02/18AVEO Oncology Announces Refinanced Debt Facility
Provides Approximately $12.1M in Additional Cash Flow Over 2018-19 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 2, 2018-- AVEO Oncology (NASDAQ:AVEO) today announced that it has completed the refinancing of its existing $20.0 million debt facility with Hercules Capital, Inc. and its affiliates, the terms of which enable approximately an additional $12.1 million in cash flow over 2018 and 2019, when compared to the prior loan. The new $20.0 million facilit... 
Printer Friendly Version